Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25541363 | 0.86 | USP2 (0.45) | USP2SMN1; SMN2TSHRALOX15GPR119 | |
| SCHEMBL20396140 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2TSHRALOX15GPR119 | |
| SCHEMBL20412573 | 0.80 | GPR119 (0.40) | USP2SMN1; SMN2GPR119 | |
| SCHEMBL19839770 | 0.80 | SCD5 (0.47) | TSHRALOX15GPR119ATMCHRM2 | |
| SCHEMBL20396153 | 0.79 | USP30 (0.40) | USP2SMN1; SMN2TSHRALOX15GPR119 | |
| SCHEMBL2422488 | 0.77 | RORC (0.41) | USP2SMN1; SMN2TSHRALOX15GPR119 | |
| SCHEMBL20412572 | 0.77 | GRM5 (0.45) | TSHRALOX15GPR119ACACBATM | |
| SCHEMBL20395989 | 0.76 | PDK2 (0.41) | SMN1; SMN2TSHRALOX15GPR119ATM | |
| SCHEMBL2649144 | 0.76 | GPR119 (0.37) | USP2SMN1; SMN2GPR119CHRM2CHRM4 | |
| SCHEMBL20395937 | 0.75 | JAK2 (0.42) | SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11661431-B2 | Thienopyrrole compounds | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365594-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | USP2 3870/4885SMN1; SMN2 4502/4885TSHR 619/4885 |
| US-11661431-B2 | Thienopyrrole compounds | SSB, TPMT, LCP2 | USP2 3870/4885SMN1; SMN2 4502/4885TSHR 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.